Yi Li

Prof. Dr. Yi Li


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 July 2015 in Chemical Science
Verified
Journal Article
Open access
PDF file
LHLiang He
Liang He
YLYi Li
Yi Li
CTCai-Ping Tan
Cai-Ping Tan
RYRui-Rong Ye
Rui-Rong Ye
MCMu-He Chen
Mu-He Chen
ZMZong-Wan Mao
Zong-Wan Mao
We report the rational design and photodynamic anticancer mechanism studies of iridium(iii) complexes with pH-responsive singlet oxygen (1O2) production and lysosome-specific imaging properties.

1 January 2015 in Biomaterials
Verified
Journal Article
Closed access
YLYi Li
Yi Li
CTCai-Ping Tan
Cai-Ping Tan
Wei ZhangWei Zhang
Wei Zhang
LHLiang He
Liang He
LJLiang-Nian Ji
Liang-Nian Ji
ZMZong-Wan Mao
Zong-Wan Mao

24 February 2020 in Dalton Transactions
Verified
Journal Article
Closed access
PDF file
WQWei-Wei Qin
Wei-Wei Qin
ZPZheng-Yin Pan
Zheng-Yin Pan
DCDai-Hong Cai
Dai-Hong Cai
YLYi Li
Yi Li
LHLiang He
Liang He
The combination of chemotherapeutic and photodynamic activities in an iridium-based molecular compound is less reported. Herein, two iridium complexes (IrC1 and IrC2) with β-carboline alkaloid ligands were designed and synthesized. Both complexes exhibited high anticancer activities with IC50 values of around 1 μM in the dark against several cell lines tested. Notably, the cytotoxicity of these two complexes against lung cancer (A549) cells increased significantly under light (425 nm) irradiation, with phototoxicity index (PI) values of 120 and 93, respectively. They were specifically enriched in the mitochondria. Cell-based assays demonstrated that IrC1 induced an increase in intracellular reactive oxygen species (ROS) levels, reduction in ATP production, mitochondrial DNA damage, an increase in lipid peroxidation levels, and proteasomal activity inhibition. Under light conditions (in some cases a two-photon laser was also applied), these effects were greatly enhanced. Overall, we have demonstrated that these iridium complexes have dual activities of chemotherapy and photodynamic therapy, which may help to design new metal-based anticancer agents for combined chemo-photodynamic therapy.

3 August 2017 in Dalton Transactions
Verified
Journal Article
Closed access
PDF file
YLYi Li
Yi Li
BLBing Liu
Bing Liu
XLXin-Ran Lu
Xin-Ran Lu
MLMengfeng Li
Mengfeng Li
LJLiang-Nian Ji
Liang-Nian Ji
ZMZong-Wan Mao
Zong-Wan Mao
Metal N-heterocyclic carbene (NHC) complexes represent a promising class of anticancer therapeutic agents. In this work, four cyclometalated iridium(III) complexes (Ir1–Ir4) containing N-heterocyclic carbene ligands have been explored as mitochondrial anticancer and photodynamic agents. These complexes are more cytotoxic than cisplatin against the cancer cells screened, can quickly penetrate into A549 cells and are mainly localized in the mitochondria. Mechanism studies show that these complexes exert their anticancer efficacy by increasing the intracellular ROS level, reducing the mitochondrial membrane potential (MMP) and inducing apoptosis. Additionally, Ir1–Ir4 exhibited two orders of magnitude higher cytotoxicity upon irradiation at 450 nm LED light. Our work provides a strategy for the design of highly effective anticancer photodynamic therapeutic agent based phosphorescent iridium complexes.

2 May 2014 in Metallomics
Verified
Journal Article
Open access
PDF file
YLYi Li
Yi Li
GLGao-Feng Liu
Gao-Feng Liu
CTCai-Ping Tan
Cai-Ping Tan
LJLiang-Nian Ji
Liang-Nian Ji
ZMZong-Wan Mao
Zong-Wan Mao
Metal/N-heterocyclic carbene (NHC) complexes hold great opportunities for the development of novel antitumor metallodrugs. Herein, four Ag(i) and Au(i

1 December 2014 in Chemical Communications
Verified
Journal Article
Closed access
PDF file
Wei ZhangWei Zhang
Wei Zhang
YLYi Li
Yi Li
JSJing-Hua Sun
Jing-Hua Sun
CTCai-Ping Tan
Cai-Ping Tan
LJLiang-Nian Ji
Liang-Nian Ji
ZMZong-Wan Mao
Zong-Wan Mao
Supramolecular self-assembled nanoparticles were constructed to overcome cisplatin resistance using a platinum(iv) prodrug and porphyrin as the host and guest molecules, respectively.